Albany - NY, Sept. 20, 2016 -- The research report indicates that the opportunity in the global active pharmaceutical ingredient market was valued at US$134.70 bn in 2015. However, this opportunity will swell to US$219.60 bn by 2023, as the market surges at a CAGR of 6.3% between 2015 and 2023. The cardiovascular drugs segment held the largest share in the overall market in 2015. In the forecast period, this segment is anticipated to expand at a CAGR of 6.63%. Geographically, North America will emerge as a leader in the global market due to a high demand for API in drug manufacturing activities and investments made in research and development. During the forecast period, this regional segment will surge at a CAGR of 5.03%.
Browse Research Report on Active Pharmaceutical Ingredient Market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html
The key players defining the competitive landscape of the global active pharmaceutical ingredient market as of 2015 were Teva Pharmaceutical Industries Ltd., Zhejiang Medicine Co., Ltd and Zhejiang NHU Co., Ltd., and North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. A critical analysis of the market suggests, these players will expand their market presence through meaningful mergers and acquisitions. The intense competition in the overall market is also being fueled by the high fixed costs and exit costs. As these expenditures for companies continue to remain high, players will focus on increasing their research and development activities to deliver result-oriented drugs.
API Sales Gain Momentum with Surging Healthcare Expenditure
The increasing healthcare budgets in recent years have been the undercurrent for the revenues flowing into the active pharmaceutical ingredient market. With exponentially growing demand for drugs, the consumption of active pharmaceutical ingredient has also increased by leaps and bounds. “Considering the population explosion, technological advancements, and ongoing scientific research projects the development of drugs will present effective solutions to a range of chronic diseases such as cancer, cardiovascular conditions, metabolic disorders, musculoskeletal disorders, and for other therapeutic uses,” says a TMR analyst.
The demand for drugs to treat the aging population will definitely boost the sale of active pharmaceutical ingredients that are popularly used for manufacturing drug products. Due to a growing pool of geriatrics in Europe and North America, these regions are primarily driving the active pharmaceutical ingredient market. Improving access to healthcare and the growing demand for pharmaceuticals in Asia Pacific and Rest of the World are likely to create lucrative growth opportunities for the overall market. Furthermore, increasing investments by manufacturers, especially in India, to adhere to the guidelines set by the U.S. FDA is also winning them big contracts, thereby increasing foreign earnings.
More Pharmaceutical Industry Research Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
Generic Drugs Act as Impediments
The promising trajectory of the active pharmaceutical market is being impeded by the empowering presence of generic drugs. The shortage of drugs, unaffordability, and poor accessibility in remote regions of several developing regions are the driving the consumption of generic drugs. However, the setting up of good manufacturing practice by the European Union is focused on mitigating this issue. These regulations will not only improve the quality of the drugs sold in the market, but also result in the sale of scientifically-developed drugs that are credited with certain approvals and quality checks.
The review of the global active pharmaceutical ingredient market is based on the report published by Transparency Market Research titled “Active Pharmaceutical Ingredient Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
Browse Press Release on Active Pharmaceutical Ingredients Market: http://www.transparencymarketresearch.com/pressrelease/active-pharmaceutical-ingredients-market.htm
The global active pharmaceutical ingredients market is segmented as follows:
Global Active Pharmaceutical Ingredients Market, by Manufacturing Process, 2013-2023 (US$ Mn)
- Captive Manufacturing
- Contract Manufacturing
Global Active Pharmaceutical Ingredients Market, by API Type, 2013 – 2023 (US$ Mn)
- Synthetic Chemical API
- Biological API
Global Active Pharmaceutical Ingredients Market, by Drug Type, 2013 – 2023 (US$ Mn)
- Branded Prescription Drugs
- Generic Prescription Drugs
- OTC Prescription Drugs
Global Active Pharmaceutical Ingredients Market, by Therapeutic Area, 2013 – 2023 (US$ Mn)
- Cardiovascular Disorders
- Metabolic Disorders
- Neurological Disorders
- Oncology
- Musculoskeletal Disorders
- NSAIDs
- Other Therapeutics Uses
Global Active Pharmaceutical Ingredients Market, by Geography, 2013 – 2023 (US$ Mn)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World (RoW)
Browse Other Research Report:
- High Potency Active Pharmaceutical Ingredient (HPAPI) Market: http://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html
About Us:
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact Us Rohit Bhisey Transparency Market Research 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com Blog: http://www.tmrblog.com/


FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 



